At the time of writing, Relay Therapeutics Inc [RLAY] stock is trading at $9.51, up 52.40%. An important factor to consider is whether the stock is rising or falling in short-term value. The RLAY shares have gain 40.06% over the last week, with a monthly amount glided 39.85%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on May 10, 2024, when Barclays upgraded its rating to a Overweight but kept the price target unchanged to $15 for it. Previously, Jefferies upgraded its rating to Hold on April 20, 2023, and kept the price target unchanged to $12.50. On April 19, 2023, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $29 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $29 on April 13, 2023. Oppenheimer initiated its recommendation with a Outperform and recommended $33 as its price target on February 03, 2023. Barclays started tracking with a Equal Weight rating for this stock on September 30, 2022, and assigned it a price target of $23. In a note dated September 02, 2022, Stifel initiated an Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Relay Therapeutics Inc fluctuated between $5.70 and $12.14. Currently, Wall Street analysts expect the stock to reach $18.63 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $9.51 at the most recent close of the market. An investor can expect a potential return of 95.9% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
According to Relay Therapeutics Inc [NASDAQ:RLAY], the company’s sales were 35.21M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -10.51%, Pretax Profit Margin comes in at -9.17%, and Net Profit Margin reading is -9.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.44 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.97 points at the first support level, and at 6.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.88, and for the 2nd resistance point, it is at 12.26.
Ratios To Look Out For
It is important to note that Relay Therapeutics Inc [NASDAQ:RLAY] has a current ratio of 15.64. On the other hand, the Quick Ratio is 15.64, and the Cash Ratio is 2.98. Considering the valuation of this stock, the price to sales ratio is 36.16, the price to book ratio is 1.86.
Transactions by insiders
Recent insider trading involved Catinazzo Thomas, Chief Financial Officer, that happened on Jul 29 ’24 when 10780.0 shares were sold., Rahmer Peter completed a deal on Jul 30 ’24 to sell 15128.0 shares. Meanwhile, Rahmer Peter sold 13523.0 shares on Jul 29 ’24.
